<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01390480</url>
  </required_header>
  <id_info>
    <org_study_id>ENM-DA-017</org_study_id>
    <nct_id>NCT01390480</nct_id>
  </id_info>
  <brief_title>Effects of Vitamin D Supplementation in Subjects With New Onset of Type 1 Diabetes</brief_title>
  <official_title>Placebo Controlled Pilot Study on Effects of Vitamin D Supplementation in Subjects With New Onset of Type 1 Diabetes on Immunological, Endocrine and Metabolic Parameters: Step 2 in the Austrian Diabetes Prevention Programme</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical University of Graz</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Medical University of Vienna</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Medical University of Graz</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this placebo controlled study the investigators aim to investigate the effects of vitamin
      D supplementation in subjects with new onset of type 1 diabetes on immunological, endocrine
      and metabolic parameters.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a bicentric, randomized placebo controlled, double blind study, with the aim to
      evaluate the effect of vitamin D supplementation in subjects with new onset of type 1
      diabetes on immunological, endocrine and metabolic parameters.

      The primary study goal is to evaluate the influence of vitamin D supplementation on the
      number and function of the master regulatory T-cells under controlled conditions within 13
      months. The secondary study goals are a comprehensive immune phenotyping to determine whether
      Vit D produces changes consistent with a general improvement in immune homeostasis that
      supports ß-cell tolerating interventions, the assessment of ß-cell function in all subjects
      to obtain preliminary data on the effects of Vit D on ß-cell survival.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2010</start_date>
  <completion_date type="Actual">February 2014</completion_date>
  <primary_completion_date type="Actual">November 2013</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Increase and function of regulatory T-cells</measure>
    <time_frame>13 months</time_frame>
    <description>The level and function of the regulatory T-cells will be compared between the two groups.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Immunophenotyping</measure>
    <time_frame>13 months</time_frame>
    <description>The effect of vitamin D on circulating immune cells and cytokine secretion at basal, after 3, 6 and 12 months.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Insulin secretion</measure>
    <time_frame>13 months</time_frame>
    <description>Insulin secretion assessed with a mixed meal tolerance test will be performed basal, after 3, 6 and 12 months.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Calcium levels</measure>
    <time_frame>13 months</time_frame>
    <description>Serum calcium levels will be measured basal, after 1,3,6,9 and 12 months.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">31</enrollment>
  <condition>Type 1 Diabetes</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>peanut oil</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vitamin D (Oleovit®)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>cholecalciferol</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cholecalciferol</intervention_name>
    <description>weekly dose (based on 70 IU/kg bodyweight/day) orally</description>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_label>Vitamin D (Oleovit®)</arm_group_label>
    <other_name>intervention: Oleovit D3</other_name>
    <other_name>Placebo: peanut oil</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  males or females &gt; 6 years

          -  new onset of type 1 diabetes (3 months)

        Exclusion Criteria:

          -  pregnancy

          -  hypercalcemia (&gt;2,65 mmol/L)

          -  chronic disease including a long-term medication over 4 weeks per year (except type 1
             diabetes)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Thomas Pieber, Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical University of Graz</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Medical University Graz</name>
      <address>
        <city>Graz</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
  </location_countries>
  <verification_date>April 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 23, 2011</study_first_submitted>
  <study_first_submitted_qc>July 7, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 11, 2011</study_first_posted>
  <last_update_submitted>April 16, 2015</last_update_submitted>
  <last_update_submitted_qc>April 16, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 17, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>vitamin D</keyword>
  <keyword>Autoimmune disease</keyword>
  <keyword>diabetes</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamins</mesh_term>
    <mesh_term>Vitamin D</mesh_term>
    <mesh_term>Ergocalciferols</mesh_term>
    <mesh_term>Cholecalciferol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

